Gujarat summit boosts Saudi-India trade ties

A 12-member delegation of Saudi Indian Business Network (SIBN) attended the eighth Vibrant Gujarat Global Summit on Jan. 10-13 at Gandhinagar, Gujarat.
Updated 24 January 2017

Gujarat summit boosts Saudi-India trade ties

A 12-member delegation of Saudi Indian Business Network (SIBN), which works under the aegis of Consulate General of India, attended the eighth Vibrant Gujarat Global Summit on Jan. 10-13 at Gandhinagar, Gujarat.
The summit brought together world leaders, ministers, corporate giants, senior policy makers and heads of international institutions and academia to further the cause of business development and to promote cooperation.
The delegation also promoted the first Indian-Expo 2017, which will be organized by MBN Luxury Lines in Association with SIBN on Oct. 22-24 at Jeddah Hilton.
The delegation met with various industry leaders and bureaucrats at the Gujarat summit.
A specific seminar on Saudi Arabia was organized in the summit to provide a platform to connect globally with potential partners to explore opportunities of collaboration and partnership.
Rajiv Kumar Gupta, principal secretary to the Gujarat government, assured the delegatioin of full help to encourage companies from Gujarat to attend the Jeddah exhibition. He confirmed that Gujarat National Fertilizers Company will participate in the Indian expo in Jeddah.
Zafar Sareshwala, chancellor of Maulana Azad National Urdu University and founder of Parsoli Group, said the intiative would expand the horizons and build stronger partnerships between two countries.
Walaa Khalil, CEO MBN Luxury Lines, said: “We recognize the favorable economic development between India and Saudi Arabia and we have seen a lot of potential in increasing trade and investment.”
Various businessmen met with the delegation and showed interest in the upcoming expo.
Zakariya Biladi, who was in charge of the SIBN delegation, said it was a big opportunity to improve bilateral relations in different areas of cooperation.


Clinical trials to accelerate adoption of new drug treatments in Saudi Arabia

Updated 27 May 2020

Clinical trials to accelerate adoption of new drug treatments in Saudi Arabia

  • Trials are being led locally as an essential means to verify the safety and effectiveness of a new drug
  • Eli Lilly has a major role to play during the coronavirus disease (COVID-19) pandemic

RIYADH: Clinical trials in Saudi Arabia could speed up the adoption of new drugs locally, a pharmaceutical executive has told Arab News.

“Clinical trials have two very big benefits for the Kingdom. Firstly, they provide data in the long run with respect to safety and efficacy, catered specifically to the Saudi population. Secondly, they impact local investment and build healthcare capabilities,” Managing Director of Eli Lilly Dimitri Livadas said..

Lividas further explained that the clinical trial phase of any new treatment is crucial as it represents the stage between the adoption or rejection of a drug. Working with the Ministry of Health and with a presence in the Kingdom for 42 years, the pharmaceutical company began research trials in the country in 2016, consisting of five pre-marketing activities and three monitoring studies for post-marketing.

Lividas added that the trials are being led locally as an essential means to verify the safety and effectiveness of a new drug before it is put to the market and introduced to patients. The majority of these are focused on diabetes, oncology, immunology, and osteoporosis.

“We genuinely believe that our future is here in Saudi Arabia. We continue to make great progress in having a commercial organization in the Kingdom that is fully staffed by Saudi nationals,” said Lividas.

As a biopharmaceutical company, Eli Lilly has a major role to play during the coronavirus disease (COVID-19) pandemic. It recently announced partnership with AbCellera to develop a treatment for the virus and aims to enter into clinical trials this year.

“I salute the Saudi authorities for their strong measures to contain the spread of COVID-19. I think it is an example to the world on how to do this. I would like to also express my gratitude toward all healthcare professionals who are currently on the frontlines, risking their own health to help others," Lividas said.